Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on October 7, 2024, providing a preliminary update on its expected financial results for the third quarter of 2024. The company anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $56 million on a pre-tax basis. This charge is a result of development milestone and up-front payments tied to collaboration and licensing agreements. This IPR&D charge is projected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43 for the third quarter. Investors should note that these are preliminary estimates, and the actual results are subject to the company's financial statement closing procedures and could differ. Regeneron emphasizes that acquired IPR&D charges are inherently unpredictable due to the uncertainty in timing and magnitude of such transactions, and therefore are not typically forecasted.
Key Highlights
- 1Regeneron expects a pre-tax IPR&D charge of approximately $56 million for Q3 2024.
- 2This charge is attributed to milestone and up-front payments for collaboration and licensing agreements.
- 3The IPR&D charge is estimated to decrease Q3 2024 GAAP and non-GAAP net income per diluted share by approximately $0.43.
- 4The reported figures are preliminary estimates and subject to finalization of financial closing procedures.
- 5Acquired IPR&D charges are not typically forecasted by Regeneron due to their unpredictable nature.
- 6The company provided a cautionary note regarding forward-looking statements and potential material differences in actual results.